National MS Registry of Iran

Farsi

Projects:

  1. Predicting the progress of the relapsing-remitting MS to the secondary progressive MS, by traditional methods and machine learning/ Ethical code: IR.TUMS.NI.REC.1404.007 (2025)
  2. Predicting the progress of the relapsing-remitting MS to the secondary progressive MS, by traditional methods and machine learning/ Ethical code: IR.TUMS.NI.REC.1404.007 (2025)
  3. Evaluation of the difference in the incidence of the first demyelinating event in relapsing-remitting MS patients/ Sina Hospital, Tehran/ Ethical code: IR.TUMS.NI.REC.1403.005 (2024)
  4. Estimating the prevalence and risk factors of multiple sclerosis in Tehran province in 2023/ Ethical code: IR.TUMS.SINAHOSPITAL.REC.1403.027 (2024)
  5. Determining ethnic risk factors in the incidence of MS among different ethnic groups in the country/ Ethical code: IR.TUMS.NI.REC.1403.012 (2024)
  6. Investigating the relationship between physical activity with multiple sclerosis disease in Guilan province/ Ethical code: IR.GUMS.REC.1403.215 (2024)
  7. Comparison of diet and sun exposure in two groups with and without multiple sclerosis in Guilan province/ Ethical code: IR.GUMS.REC.1403.111 (2024)
  8. Survey of the type and frequency of non-MS drugs in multiple sclerosis patients registered in MS registry system of Guilan/ Ethical code: IR.GUMS.REC.1403.523 (2024)
  9. Registry system in patients with multiple sclerosis in Razavi Khorasan province (2023)
  10. Compilation of educational packages of the national registration website for MS and NMO diseases/ Ethical code: IR.TUMS.NI.REC.1402.011 (2023)
  11. Expansion of Iran’s national MS registry: the third development of information on patients with multiple sclerosis/ Ethical code: IR.TUMS.NI.REC.1402.072 (2023)
  12. Determine risk factors between cigarette and water-pipe smoking, drug and alcohol abuse and late onset multiple sclerosis (LOMS)/ Ethical code: IR.TUMS.NI.REC.1402.028 (2023)
  13. Factors influencing the conversion of Relapsing-Remitting Multiple Sclerosis to the Secondary-Progressive in Iran/ Ethical Code: IR.TBZMED.REC.1402.078 (2023)
  14. Investigating the relationship between smoking, hookah, drugs, alcohol, exposure to sunlight, medical history and stressful life events on multiple sclerosis patients in Kermanshah (2023)
  15. Investigating the relationship between nutritional, hormonal and physical activity factors with multiple sclerosis (2023)
  16. Registry system in patients with multiple sclerosis in Isfahan province and it’s followed up (2022)
  17. Second development of registry system in patients with MS in Iran/ Ethical code: IR.TUMS.NI.REC.1401.063 (2022)
  18. Precision medicine of multiple sclerosis patients using the demographic characteristics of Iran’s MS registration system/ Ethical code: IR.TUMS.NI.REC.1401.075 (2022)
  19. Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning via Iranian MS Society (IMSS) registry system data/ Ethical code: IR.TUMS.NI.REC.1401.101 (2022)
  20. Rate of Urological disorders among multiple sclerosis patients in Tehran province during 2018-2022/ Ethical code: IR.TUMS.NI.REC.1401.103 (2022)
  21. Evaluating the Influential Factors on the Time of Diagnostic Delay among Patients with Multiple Sclerosis in Iran/ Ethical code: IR.TUMS.NI.REC.1401.048 (2022)
  22. Strategic Analysis “National registry System of Patients with Multiple Sclerosis in Iran” (2022)
  23. A Grounded Theory Approach to Understanding Psychological Trauma, Dissociation and Emotion in M.S Patients/ Ethical code: IR.TUMS.NI.REC.1401.015 (2022)
  24. Registry system in patients with multiple sclerosis in Yazd province (2022)
  25. Prevalence of Multiple sclerosis and its clinical and demographic characteristics in Kurdish populations in western Iran (2021-2022)
  26. Investigating the trend of changes in the administration of MS drugs from 2018-2021 (2021)
  27. Evaluation of Demographic, Clinical, and Laboratory Characteristics of Covid-19 in Patients with MS (2021)
  28. Prevalence of cancer and its types in the population of MS patients in Gilan province in 2021 (2021)
  29. Evaluation of side effects of Sinopharm and AstraZeneca vaccines in patients with MS in Kermanshah (2021)
  30. Six-month follow-up of complications and consequences of MS patients after injection of Sinopharm and AstraZeneca vaccines in Kermanshah (2021)
  31. A Discriminant Analysis-based Prediction Model for COVID-19 and its Severity in MS Patients/ Ethical code: IR.TUMS.MEDICINE.REC.1400.1137 (2021)
  32. Evaluation of the relationship between the type and degree of disability with number of deliveries and abortions in patients registered in the Iranian MS registration system (2021)
  33. Socio-economic status of patients with MS according to the registered information of patients in Iran (2021)
  34. The demographic characteristics and estimation of prevalence of MS in Kermanshah province in 2020 by sex and age groups/ Ethical code: IR.TUMS.NI.REC.1400.017 (2021)
  35. Registry system in patients with multiple sclerosis in Kerman province (2021)
  36. Registry system in patients with multiple sclerosis in Lorestan province – Iran (2021)
  37. Epidemiology of familial MS prevalence and risk factors in Tehran, Isfahan, Fars, Mazandaran, Kermanshah and Charmahal-bakhtiyari province during 2019-2021/ Ethical code: IR.TUMS.NI.REC.1399.034 (2021)
  38. Registry system in patients with multiple sclerosis in Qom province from 2020 to 2021 (2021)
  39. A survey of side effects of Sinopharm and Astrazeneca vaccines in patients with multiple sclerosis in Kermanshah (2021)
  40. Training to register Multiple Sclerosis patients’ of Iran (2020)
  41. Investigating the Impact of Chronic Diseases history, before Diagnosing Multiple Sclerosis in Delayed Diagnosis in MS Patients/ Ethical code: IR.TUMS.NI.REC.1399.029 (2020)
  42. Designing corona virus registration system among patients with MS in Iran/ Ethical code: IR.TUMS.NI.REC.1399.028 (2020)
  43. Prevalence of smoking in Isfahan and the difference between symptoms and clinical manifestations of MS in smokers and non-smokers patients (2020)
  44. Comparison of the registry of multiple sclerosis in Iran in comparison with other countries in the world (2020)
  45. Prevalence of positive family history and its relationship with demographic characteristics, symptoms and clinical course of the disease in patients with MS of Isfahan from 2018 to 2019 (2020)
  46. Registry system in patients with multiple sclerosis in West Azerbaijan province (2020)
  47. Evaluating MS prevalence in Tehran in 2020 and its future by Using Time Series Methods
  48. Familial MS in the Mazandaran province and its disability association compares to non-familial types
  49. Predictive value of olfactory and taste disorders outcome of Covid-19 and its process of recovery in MS patients referred to Bu Ali Sina Medical Center in Qazvin Province in 2020
  50. Prevalence of probable cases of Covid-19 in patients with MS receiving Rituximab in Qazvin Province from 2019 to 2020
  51. Explaining the individual problems experienced of women affected by Neuromyelitis Optica and Multiple Sclerosis: A comparative content analysis Study/ Ethical code: R.TUMS.NI.REC.1399.01 (2019)
  52. Validity and reliability of national Multiple sclerosis questionnaire for registry system in Iran/ Ethical code: IR.TUMS.VCR.REC.1397.361 (2018)